Research
Hormonal
Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate promote satiety and improve metabolic health by stimulating GLP-1 and PYY secretion and modulating gut-brain signaling, despite inconsistent fecal level measurements in obesity.
Consume fiber-rich foods to support SCFA production. This supports satiety hormones (GLP-1/PYY) and gut health, even if direct measurement of SCFAs is not feasible.
GoodSupportsHIGH confidence
SCFAs modulate appetite and energy expenditure through gut-brain signaling. They stimulate secretion of anorexigenic hormones such as GLP-1 and PYY via FFAR2 and FFAR3 receptors on enteroendocrine cells.
Why this rating
Strong mechanistic evidence from animal and human studies, though human fecal data is inconsistent.
Source
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Davide Masi et al. · Cell Reports Medicine · 2026
DOI 10.1016/j.xcrm.2025.102573
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary patterns significantly shape the gut microbiome, with fiber-rich diets increasing diversity and beneficial bacteria, while high-fat diets decrease diversity and promote pro-inflammatory species.Strong
- Reduced gut microbial diversity (alpha-diversity) and specific taxonomic shifts (e.g., depletion of Akkermansia muciniphila and Faecalibacterium prausnitzii) are consistently associated with obesity and metabolic syndrome, serving as a marker of a less resilient microbiome.Good
- Elevated circulating branched-chain amino acids (BCAAs) and imidazole propionate (IMP) are causally linked to insulin resistance and type 2 diabetes, serving as predictive biomarkers years before clinical onset.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →